Heidi Health Raises $340M to Move Its Clinical AI Beyond Doctor’s Notes

Heidi Health now has $340 million in new financing to pursue a bigger role in the clinical workday: helping clinicians act on care, not just record it. The company announced a $100 million Series C and a separate $240 million growth investment. Its planned AI features would handle work around patient visits under clinician supervision.

Two investments with different purposes

Blackbird led the equity round, joined by existing investors Phoenix Court, Point72 Private Investments and Headline. General Catalyst’s Customer Value Fund led the growth investment. Heidi’s funding announcement says the second investment gives it capacity to spend on wider adoption in health systems.

The $340 million headline does not describe one equity round. Streamline Feed describes the $240 million portion as a non-dilutive, revenue-based facility: General Catalyst would cover sales, marketing and customer-acquisition costs in return for a capped share of revenue generated by that spending. It is not a second sale of company shares. Specific repayment terms were not disclosed.

The work beyond the visit note

Heidi’s existing software captures consultations and prepares documentation such as medical notes and referral letters. Its Evidence product gives clinicians clinical guidance while they work; Heidi says it has answered more than 10 million queries since launching in March 2026. The next step it is funding is meant to help carry out tasks around patient visits.

Heidi plans supervised AI features for preparing pre-visit chart summaries, engaging patients and managing follow-up administration. Chief executive Thomas Kelly described the shift as moving from documenting care to helping clinicians act on it. These are planned capabilities, not established deployment results.

Heidi says clinicians will remain in control of decisions. Some financing will support clinical evidence, quality-management systems and regulatory submissions. The company says the coming capabilities will not be available in the UK or EU. Its current UK deployment should not be mistaken for availability of those planned features there.

Scale is not the same as supervised action

Heidi says its existing platform has supported more than 175 million patient visits and is used in 190 countries and 110 languages. It reported annual recurring revenue of $50 million in April 2026, up from $1 million two years earlier. Those figures describe reach and commercial growth, not how well its planned supervised tasks will work.

Beth Israel Lahey Health uses Heidi in the US, and Heidi was selected as sole supplier for NHS England Midlands. Streamline Feed says the Midlands selection covers 15 trusts, every integrated care board in the region and 1,239 general practices. Heidi puts its enterprise activation rate at about 62% since its Series B, though it does not define that measure.

The Series C values Heidi at $900 million, the company says. Streamline Feed puts its Series B valuation at $465 million. Investors are backing a growing documentation business and a proposed move into more consequential work. Heidi’s next test is whether it can make that move while keeping clinical decisions with clinicians and meeting its stated safety requirements.